Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling

Key Terms

subjective cognitive decline medical

Subjective cognitive decline is when an individual notices a persistent drop in their memory or thinking abilities even though standard medical tests may still appear normal. Investors watch this because it can signal early demand for diagnostics, therapies and clinical trials—like hearing a faint engine noise before a mechanic can find a fault—so growing rates or research activity around it can affect healthcare companies’ prospects and future revenue streams.

amyloid (Aβ42/Aβ40 ratio) medical

The amyloid Aβ42/Aβ40 ratio compares two forms of the amyloid-beta protein found in the brain and body fluids; a lower ratio usually signals a relative increase in the longer Aβ42 species that more readily clumps into plaques. Investors care because this biomarker is used to gauge the presence or progression of Alzheimer’s disease and to judge whether experimental drugs are hitting their target, much like a thermometer that helps decide if a treatment is working and therefore influences clinical success, regulatory approval, and market value.

p-Tau 217 medical

p-tau 217 is a form of the tau protein that carries a specific chemical tag at one spot (site 217) and can be measured in blood or spinal fluid as an early signal of Alzheimer’s-type brain damage. Like a smoke alarm sensing early signs of a fire, rising p-tau 217 levels help doctors and researchers spot disease earlier, guide who qualifies for trials, and influence the demand for diagnostics and therapies—factors that affect healthcare spending and investment opportunities.

multi-analyte technical

A multi-analyte test or product measures several biological markers or substances at once instead of testing for one item at a time. For investors, it matters because combining multiple checks into a single test can lower costs, speed up decision-making, and open larger markets by offering richer information—similar to getting a multi-point inspection instead of separate single checks—while also bringing greater technical and regulatory complexity.

laboratory developed tests regulatory

Laboratory developed tests are medical diagnostic tests that are designed, built and performed by a single clinical laboratory for use within that same lab rather than sold as a finished product by a manufacturer. For investors, they matter because they represent a faster path to bringing new diagnostics to patients but carry regulatory, reimbursement and scalability risks—think of a chef crafting a custom dish in their kitchen versus a food company mass-producing a packaged item.

restricted stock units (RSUs) financial

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Analysis of Subjective Cognitive Decline (SCD) cohort indicates that combining biomarkers representing four key biological axes—amyloid, tau, neurodegeneration, and neuroinflammation—provides a superior window into disease progression at the earliest stages

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the high impact journal JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842215. The study, led by researchers at Amsterdam UMC, followed a cohort of nearly 300 individuals for up to 15 years. The findings demonstrated that while individual biomarkers provide a baseline snapshot of pathology, the combination of multiple markers at baseline—along with their subsequent longitudinal trajectories—offers a significantly more comprehensive view of clinical risk.

The research utilized ultra-sensitive Simoa^® technology to measure biomarkers representing the four critical biological axes of Alzheimer’s disease: amyloid (Aβ42/Aβ40 ratio), tau (p-Tau 217), neuroinflammation (GFAP), and neurodegeneration (NfL). A primary conclusion of the study was that the most accurate assessment of clinical progression was achieved through a multi-analyte model, both at baseline as well as through longitudinal monitoring of individual biomarker values. The optimal model achieved a C-index of 0.90 (1.0 being perfect accuracy) for identifying individuals with SCD—the earliest stage where patients notice potential changes that are undetectable in objective cognitive testing–most likely to progress toward clinical impairment. The data showed that even a single baseline measurement of this specific multi-analyte panel offered a distinct prognostic advantage over standalone p-Tau 217 assays.

This JAMA paper highlights how Quanterix’s Simoa^® ultra-sensitive technology and multiplexed biomarker assays are powering advances in Alzheimer’s disease research, which is becoming increasingly focused on evaluating multiple biomarkers and multiple disease pathways. Quanterix is also leading the way in Alzheimer’s diagnostics with scalable multi-marker laboratory developed tests, such as LucentAD Complete which is designed with same biomarkers evaluated in the JAMA study. As the company’s first algorithmic multi-analyte test for amyloid pathology risk in symptomatic individuals, LucentAD Complete stands alone in providing both an overall amyloid risk score and individual results for these same biomarkers alongside normative reference ranges.

"Identifying which pre-symptomatic individuals among the ‘worried well’ are likely to progress to objective clinical symptoms is a critical challenge for patient care and efficient clinical trial enrollment. The data in our study represent a significant step forward in identifying the 'fast progressors' within the pre-clinical continuum," said Charlotte Teunissen, Ph.D., Professor in Neurochemistry at Amsterdam UMC. "By observing baseline p-Tau 217, GFAP, NfL, and Aβ42/40, and how p-Tau 217 and GFAP levels evolve over time, we see clearly that a multi-analyte signature provides the nuanced prognostic picture required for the next generation of Alzheimer’s risk assessment."

"We view these findings as a strong endorsement of the foundational science that informs our multi-analyte approach," said Michael Miller, Chief Operating Officer at Quanterix. "As our first multi-analyte laboratory developed test for amyloid pathology that leverages Simoa multiplexing technology, LucentAD Complete was designed to provide a comprehensive view of amyloid risk in symptomatic individuals. As the field moves toward more personalized, longitudinal care, we aim to develop additional differentiated tools that leverage these insights to further impact the future of clinical management and the identification of high-risk individuals for the earliest possible intervention."

About Quanterix

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa^® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,000 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company^®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260121870977/en/

Study Media Contact:

Charlotte Teunissen, Ph.D.

Professor in Neurochemistry at Amsterdam UMC

c.teunissen@amsterdamumc.nl



Quanterix Media Contact:

media@quanterix.com



Investor Relations Contact:

Joshua Young

(508) 846-3327 - mobile

jyoung@quanterix.com    

Source: Quanterix Corporation